NLR与肿瘤同步放化疗预后的相关性研究

Correlation between NLR and prognosis of concurrent chemoradiotherapy

目前肿瘤治疗的临床方法主要是手术、放射治疗、化学药物治疗、中医学方法等综合治疗,然而有一些肿瘤由于起病隐匿,初次诊治已经进入中晚期,丧失手术机会,无法通过准确的手术分期评估预后。根治性同步放化疗可用于已无法手术治疗且放射治疗敏感的肿瘤。因此,探寻准确、经济的指标以评估放化疗预后已成为热点。中性粒细胞/淋巴细胞比值(Neutrophil to lymphocyte ratio,NLR)指治疗前外周血中中性粒细胞与淋巴细胞的比值,作为全身性的整体炎症反应指标,已有诸多研究证实其与肿瘤放化疗疗效的相关性,为评价肿瘤的预后提供了新的思路。本文对NLR与肿瘤同步放化疗预后相关性进行简要综述。

By now,the clinical methods of cancer treatment are mainly surgery,radiotherapy,chemotherapy,and traditional Chinese medicine methods.However,some tumors are concealed due to onset,initial diagnosis and treatment,which have entered the middle and late stage,lost the operation opportunity and impossible to pass accurate surgical staging by assessment of prognosis.Radical concurrent chemoradiotherapy can be used for tumors that are inoperable and sensitive to radiation therapy.Therefore,it has become a hot spot to explore accurate and economic indicators to evaluate the prognosis of radiotherapy and chemotherapy.Neutrophil to lymphocyte ratio(NLR)refers to the ratio of neutrophils to lymphocytes in peripheral blood before treatment.As a general indicator of systemic inflammatory response,many studies have confirmed that the relationship between the efficacy of radiotherapy and chemotherapy for tumors provides a new way to evaluate the prognosis of tumors.This article briefly reviews the relationship between NLR and the prognosis of tumor-controlled radiotherapy and chemotherapy.